Comorbidities and cancer Applications to non small cell lung cancer
|
|
- Annis Higgins
- 6 years ago
- Views:
Transcription
1 Comorbidities and cancer Applications to non small cell lung cancer Pr A. Vergnenègre Dr H. Le Caer CHU Limoges CH Draguignan 1
2 Comorbidities and cancer Why? 2
3 Epidemiology elderly among lung cancer Source Framcim 43,2% 44,7% 44,9% ,7% 43,0% 39,4% ,4% 42,5% males < 70 y 70 y 3
4 Epidemiology elderly among lung cancer Source Framcim 45,1% ,5% ,4% ,7% ,6% ,6% ,5% ,9% Females < 70 y 70 y 4
5 Background Comorbidities = prognosis factor for cancer Consequences on patient s clinical pathway diagnosis ----> treatment Ex : - severe COPD limitation to thoracic surgery - severe congestive heart failure limitation to the use of some cytotoxic drugs 5
6 Clinical pathway Ambulatory care Evaluation Treatment Follow up End of life Process Screening Specialists Treatments Consultations Procedures Terminal care Result Detection Stage of disease Response Toxicity Relapse Controlled disease Survival without progression Death Death du to intercurrent event 6
7 Comorbidities and cancer Are there good tools for comorbidities assessment? 7
8 Charlson comorbidity index, CCI Charlson ME, et al : J Chron Dis 1987;40:5, diseases with weight from 1 to 6, prédictive of death +++ Comorbidity Score Myocardial infarction Congestive heart failure 1 1 Arteritis (peripheral vascular) 1 Cerebral diseases (except hemiplegia) 1 Dementia 1 Chronic obstructive pulmonary diseases 1 Systemic diseases 1 Gastro-duodenal ulcer 1 Hepatic failure (mild) 1 Diabetes mellitus without complication 1 Diabetes mellitus with another involved organ 2 Hemiplegia 2 Renal failure (moderate to severe) 2 Other solid tumors without metastasis 2 Leucemia 2 Lymphoma or Myeloma 2 Hepatic failure (moderate to severe) 3 VIH infection 6 TOTAL 8
9 Charlson comorbidity index, CCI Overall survival according to CCI, p<0,001 9
10 Charlson s age comorbidity index Charlson ME, et al : J Clin Epidemiol 1994;47: gage Score Global score: age + comorbidities 10
11 Charlson s age comorbidity index Age-Comorbidity score Estimated relative risk (1.25, 1.68) 2.10 (1.57, 2.81) 3.04 (1.96, 4.71) 4.40 (2.45, 7.90) 6.38 (3.07, 13.24) 9.23 (3.84, 22.20) (4.81, 37.22) (6.01, 62.40) 11
12 Charlson s age comorbidity index Overall survival for patients >75 according to CCI Comorbidity score : > 4 12
13 EVALUATION Other index : adult comorbidity evaluation 27 (27 conditions) Simplified comorbidity score SCS: Colinet et al. Br J Cancer 2005;93: Tabacco (7), diabetes mellitus (5), Renal failure (4), Resp diseases, cancer, heart failure, alcoholism (1) 13
14 Adult comorbidity evaluation 27 Read, JCO 2004;22: cancers. Adult index 27 Prognosis according to severity Lung colon prostate breast Relationship to stage but important variable for analysis 14
15 Adult comorbidity evaluation 27 Impact of comorbidities according to cancer type 15
16 Comorbidity scores Other index : adult comorbidity evaluation 27 (27 conditions) Simplified comorbidity score SCS: Colinet et al. Br J Cancer 2005;93: Tobacco (7), diabetes mellitus (5), renal failure (4), Resp diseases, cancer, heart failure, alcoholism (1) 16
17 Simplified comorbidity score SCS: Colinet et al. Br J Cancer 2005;93: Comorbidity Tobacco consumption Diabetes mellitus Renal insufficiency Respiratory comorbidity Cardiovascular comorbidity Neoplastic comorbidity Alcoholism Weighting
18 Simplified comorbidity score SCS: Colinet et al. Br J Cancer 2005;93: P<0,01 18
19 Comorbidity tools weaknesses : - hypothesis : each item has the same accuracy for any disease - some items refer to the studied disease (eg : cancer, weight loss, anemia, ) 19
20 Data recording Clinical Patient s Retrospective Administrative Register trials cohorts data claims Severity Comorbidities Cancer s data Patient s characteristics (PS, social) /- +/- Generalisation costs
21 Comorbidities and cancer Applications to Non small cell Lung Cancer (NSCLC) 21
22 Epidemiology 80% NSCLC 75 % stage III or IV Comorbidities : étude IFCT 1540 patients >70 y : 52.6% COPD 37% hypertension 18.6% ischemial heart disease 17.6% arteritis 14;2% diabetes 7.7% stroke Quoix, IASLC 2005, P382 S215 22
23 Survival in elderly lung cancer Follow up 12 months* : 1509 patients Death 811 (53,7%) Cancer 645 (79.5%) Comorbidities 114 (14.1%) Toxicities 40 (4.9%) Unknown 12 (1.5%) * 139 withdrawal data Quoix, IASLC 2005, P382 S215 23
24 Elderly patients are more frequently untreated 1648 patients, Median 76 y [70-96] Treatement y y y > 85 y P BSC (%) < Surgery (%) Mediastinal radiotherapy (%) Palliatie cerebral radiotherapy (%) Chemotherapy (%) E. Quoix, IASLC 2005, P-382 S215 24
25 Impact of comorbidities in elderly patients 1255 patients, with 481 patients in the ACT trial and 774 patients in the ANSCLC trial Median age: 61.2 years ( ); 428 patients were 65 years 391 (31%): other medical conditions (besides NSCLC) 310 (25%): CCI score of 1, 81 (6%) CCI score of 2 or higher Comorbidity rates were higher in : older patients, male, squamous histology Comorbidity rates were lower in : Patients with weight loss 5% (31% vs 37%, p = 0.04) Patients with time from diagnosis to randomization < 6 months (p=0.004) Asmis, PAsco 2006,abstr
26 Impact of comorbidities in elderly patients Dose intensity Age and comorbidity were associated with lower total dose in the ANSCLC trial while only age predicted for a lower total dose in the ACT trial Toxicity (univariate analysis) * Comorbidities associated with more grade 3-5 infection (p=0.03) and GI toxicity (p=0.022), pain (p=0.01), nausea (p=0.04) * Age 65 was associated with grade 3-5 neurologic toxicity (p<0.0001), GI toxicity (p=0.03), fatigue (p=0.01) Asmis, PAsco 2006,abstr
27 Impact of comorbidities in elderly patients Multivariate analysis (overall survival) Variable H R (95% C.I.) P value C C I ( ) 0.03 C C I ( ) 0.75 Age ( ) 0.72 Female 0.79 ( ) ECOG ( ) < ECOG ( ) Hgb < ( ) Inc Alk Phos 1.25 ( ) Asmis, PAsco 2006,abstr
28 Impact of comorbidities in elderly patients % survival Score 0 Score =1 Score > CCI 1 : p = HR 1.28 (95% CI ) CCI 2+ : p = 0.52 HR 1.09 (95% CI ) Months Asmis, PAsco 2006, abstr
29 Impact of comorbidities in elderly patients Comorbidity is common in patients with NSCLC, and occurs in 42% of patients over the age of 65 Males, in general, had more comorbidity than females (35% vs 21%, p<0.0001) While the elderly received less chemotherapy, they derive the same benefit as younger patients in terms of overall survival and they should not be excluded from clinical trials. However, the presence of comorbidity is associated with a poorer outcome. Asmis, PAsco 2006,abstr
30 Comorbidities and lung cancer Surgical patients : stage I NAPC D. Moro-Sibilot, ERJ 2005;26:480-6 Charlson 0 : 47% 3-4 : 8% 1-2 : 43,7% : 0,8% Charlson 2 survival prognosis factor : OR 1,81 (1,25; 2,63) 30
31 Comorbidities and lung cancer A multicenter phase II study of docetaxel/gemcitabine weekly in advanced non-small cell lung cancer (NSCLC) in elderly and/or poor performans status patients : preliminary results of the Groupe Français de Pneumo-Cancérologie (GFPC) study H.LeCaer, C.Gimenez, C.Chouaid, H.Jullian, J. Le Treut, P. Bombaron, L. Gérinière, S. Hominal, P. Dominique, J. Auliac Lung Cancer 2005, 49:S262 31
32 Comorbidities and cancer Inclusion criteria according age, CCI, PS Age [Charlson] Comorbidities Charlson score PS Treatment [2] 0-2 [2-4] 0-1 Non eligible 0-2 [2-4] 2 D + G 3-4 [5-6] 0-1 D + G 3-4 [5-6] 2 D 5-6 [7-8] 0-2 D 0-1 [3-4] 0-1 D + G [3] 0-1 [3-4] 2 D 2-5 [5-8] 0-2 D [4] 0 [4] 0-1 D + G 1-4 [5-8] 0-1 D 32
33 Comorbidities and cancer Phase II trial, 32 french hospitals; Primary objective: efficacy: OR after 3 chemotherapeutic cycles: Arm A docetaxel 30mg/m² weekly 6 weeks followed by two rest weeks Arm B docetaxel 30mg/m² plus gemcitabine 900mg/m² (G only at D1,8,22,29) followed by two rest weeks Secondary objectives: toxicity, TTP,QoL, survival. 33
34 Patients characteristics Arm A (D) Arm B (D+G) Age mean (years) [70-84] [64-82] ECOG 0 22% 42% PS 1 46% 54% 2 32% 4% Charlson mean 1,9 0,8 [0-5] [0-4] Comorbidities mean Age + Charlson [3-8] [2-6] Weight loss >10% 22% 23.9% 34
35 Toxicity Arm A (D) Arm B (D+G) N Delivered cycles (n) All grades (n) Grades 3/4 Tox 30 (20.6%) 71 (26,1%) Anemia 2 6 Neutropenia 0 16 Thrombopénie 0 3 Thrombocyemia 0 1 Fever 0 1 Fatigue Diarrhea 1 2 Constipation 1 3 Nausea/Vomiting 1 2 Bleeding 0 1 Infection 3 4 Congestive heart failure 1 2 Pulmonary 4 2 Neurological 1 3 Vascular 1 3 Pain 0 1 Alopecia 0 5 Red cell transfusions 4 pts (8%) 7 pts (14,9%) 35
36 Results ARM A (D) ARM B (D+G) Eligible Pts n (%) 50 (100) 50 (100) Evaluable Pts n (%) 39 (78) 42 (84) Partial response n (%) 5 (12,8) 17 (40,5) Stable n (/%) 14 (35,9) 18 (42,8) Controled diseases 19 (48,7%) 32 (83,3%) Progression n (%) 20 (51,3) 7 (16,6) TTP (jours) Median survival (month) 4,33 6,6 Median number of cycles 1 ( 8 weeks) 1,6 (12.8 weeks) 36
37 Quality of life assessment MEAN INITIAL SCORE ARM A (D) ARM B (D+G) LCSS SCORE (0-10) N=44 N=44 ANOREXIA 3,58 3,15 FATIGUE 4,14 3,53 COUGH 2,7 1,89 DYSPNEA 3,44 3,1 HEMOPTYSIS 0,74 0,43 PAIN 2,46 2,35 SYMPTOM score 2,84 2,40 CONSEQUENCES ON DAILY ACTIVITY 3,62 3,28 GLOBAL QoL 3,31 3,16 SPITZER SCORE (0-10) N=44 N=43 GLOBAL SCORE 7 7 No difference at initial score between progressive and controled patients in each arm. No difference in each arm between initial score and at the end of the treatment. 37
38 Comorbidities and cancer ITTpatients Symptom score Treatment A 38
39 Comorbidities and cancer ITTpatients Symptom score Treatment B 39
40 Comorbidities and cancer new tool : Lecaer, Balas (CHU Nice) Elderly description: geriatric index Denutrition Mental assessment ADL, IADL Associated to precedent results 40
41 Relationships between PS, charlson index and geriatric assessment Dujon et al, Rev Mal Resp 2006, in press 41
42 Relationships between PS, charlson index and geriatric assessment Dujon et al, Rev Mal Resp 2006, in press 42
43 Comorbidities and cancer Inclusion criteria 43
44 Comorbidities and cancer Inclusion criteria AGE(CHARLSON) IADL ADL GROUPE <<VULNERABLE>> SYNDROMES GERIATRIQUES COMORBIDITE CHARLSON PS TRAITEMENT INCLUSION [2] < INCLUSION < INCLUSION INCLUSION 70-79[3] < INCLUSION < INCLUSION 80-89[4] INCLUSION < INCLUSION 44
45 Quality of life (IRIS scale) 45
46 Cognitives and sensorial functions 46
47 DISCUSSION 47
48 Group 1 : independant patient - No severe cardiac or pulmonary comorbidity (grade >2) - No untreated comorbidity - ADL > 4/6 et IADL > 4/6 - Age < 80 - Weight loss <15 % of body weight -Clocktest = 2/2 - No fall within the last 3 months - Creatinin clearance > 50 ml/min 48
49 Group 2 : vulnerable patient - 1 or 2 not controlled or not treated comorbidities - ADL < 4/6 or IADL< 4/6 - Age > 80 - Fall within the last 3 months - Positive depression test - Weight loss between % of body weight - Creatinin clearance < 50 ml /min -Clocktest <2 49
50 Group 3: frailed and dependant patients - More than 2 comorbidities not controlled or not treated -ADL < 4 - IADL abnormal on 3 evaluable items or more - Weight loss >35 % of body weight - Creatinin clearance< 30 ml/min 50
51 Comorbidities and cancer Patient s refusal Or non proposition of treatment Interest of observational studies according to non diagnosed or non recorded diseases (dementia) 51
52 Conclusion Comorbidities: major item for cancer Clinical pathway: comorbidities have major impact on management Severity is a very important dimension Major role for elderly 52
53 Conclusion Future : Patient: center of strategy management Geriatric oncology associated with multi disciplinary staff Clinical research with social dimension 53
Maintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationClinical Activity Lung Cancer. Andrea Camerini Ospedale Versilia
Clinical Activity Lung Cancer Andrea Camerini Ospedale Versilia The three main objectives in advanced NSCLC 1. In advanced/metastatic cancer, palliation is often the primary treatment goal 2. Potential
More informationOriginal Article. Keywords: Elderly; non-small cell lung cancer (NSCLC); geriatric; therapeutic; erlotinib; chemotherapy
Original Article Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase
More informationTreatment of advanced NSCLC in the elderly. Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy)
Treatment of advanced NSCLC in the elderly Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) Most cancer patients are aged >65 years Ovary Breast NHL Corpus uteri Leukaemias
More informationUpdate on Chemotherapy- Induced Anemia and Neutropenia Therapies
Update on Chemotherapy- Induced Anemia and Neutropenia Therapies ASCO 2007: Update on Chemotherapy- Induced Anemia and Neutropenia Therapies Safety and efficacy of intravenous iron in patients with chemotherapyinduced
More informationCancer Treatment in Elderly Patients. Greg Hart Clinical Oncologist GVI Oncology
Cancer Treatment in Elderly Patients Greg Hart Clinical Oncologist GVI Oncology Ovarian Cancer Cervical Cancer Uterine Cancer Cancer in the Elderly 59% of all cancers occur in over 65 s, 30% in over
More informationComorbidities in Multiple Myeloma
Comorbidities in Multiple Myeloma Michel Delforge, MD, PhD University Hospital Leuven Leuven, Belgium COMy, Bangkok 12 may 2014 Comy Meeting, Bangkok, 12 may 2014 Disclosures Advisory board: Janssen,
More informationWhat is New in Geriatric Oncology: The Medical Oncology Perspective. Arti Hurria, MD Director, Cancer and Aging Research Program City of Hope
What is New in Geriatric Oncology: The Medical Oncology Perspective Arti Hurria, MD Director, Cancer and Aging Research Program City of Hope Cancer Incidence in the U.S. Between 2010 and 2030, cancer incidence
More informationSupplementary Material
1 Supplementary Material 3 Tumour Biol. 4 5 6 VCP Gene Variation Predicts Outcome of Advanced Non-Small-Cell Lung Cancer Platinum-Based Chemotherapy 7 8 9 10 Running head: VCP variation predicts NSCLC
More informationOncologic Care for Old-Aged Patients
Oncologic Care for Old-Aged Patients Elderly & Cancer People 65 years or older are at the higher risk for cancer. For all cancers combined, those over 65 years have an incidence rate 10 times greater than
More informationNCCTG Status Report for Study N September 2007
Phase I/II Study of Concurrent Chemotherapy and Escalating Doses 3-D Conformal Radiotherapy (RT) Followed by Three Cycles of Chemotherapy for Unresectable Non-Small Cell Lung Cancer (NSCLC) Using a New
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationFUJI study: Follow-Up of Jevtana in real life
Pharmacologie médicale Bordeaux PharmacoEpi CIC Bordeaux CIC1401 FUJI study: Follow-Up of Jevtana in real life French retrospective and protective multicenter observational study describing the survival,
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationLUNG CANCER TREATMENT: AN OVERVIEW
LUNG CANCER TREATMENT: AN OVERVIEW KONSTANTINOS N. SYRIGOS, M.D., Ph.D. Αναπλ. Καθηγητής Παθολογίας-Ογκολογίας, Ιατρικής Σχολής Αθηνών. Διευθυντής Ογκολογικής Μονάδας, Νοσ. «Η Σωτηρία». Visiting Professor
More informationElements for a Public Summary
VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Lung cancer is one of the most common types of cancer in European men and women. There are two main types of lung cancer: small
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationCombining Lurbinectedin and Doxorubicin The UCLH Experience in Small Cell Lung Cancer
Combining Lurbinectedin and Doxorubicin The UCLH Experience in Small Cell Lung Cancer Dr Martin Forster MD PhD Clinical Senior Lecturer in Experimental Cancer Medicine Consultant in Medical Oncology UCL
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationStem cell transplantation in elderly, but fit multiple myeloma patients
Stem cell transplantation in elderly, but fit multiple myeloma patients Mohamad MOHTY, MD, PhD Clinical Hematology and Cellular Therapy Dpt. Université Pierre & Marie Curie, Hôpital Saint-Antoine INSERM
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationComorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care AF symptoms Tachycardia
Supplementary Table S1 International Classification of Disease 10 (ICD-10) codes Comorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care I48 AF
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationBCCA Protocol Summary for Curative Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, Capecitabine and Radiation Therapy
BCCA Protocol Summary for Curative Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, and Radiation Therapy Protocol Code: Tumour Group: Contact Physician: GICART Gastrointestinal
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationSupplementary Table 1: Summary of 33 Patients Treated with Abemaciclib in Dose Escalation
Supplementary Table 1: Summary of 33 Patients Treated with Abemaciclib in Dose Escalation Cohort Dose and Frequency Age and Sex Tumor Type Number of Cycles Best Overall Response 4M Colorectal cancer -
More informationArm A: Induction Gemcitabine 1000 mg/m 2 IV once a week for 6 weeks.
ECOG-4201 (RTOG Endorsed) ECOG 4201 Pancreas (RTOG Endorsed)-1 Protocol Status: Opened: April 10, 2003 Closed: December 15, 2005 Title: A Randomized Phase III Study of Gemcitabine in Combination with Radiation
More informationRisk of Fractures Following Cataract Surgery in Medicare Beneficiaries
Risk of Fractures Following Cataract Surgery in Medicare Beneficiaries Victoria L. Tseng, MD, Fei Yu, PhD, Flora Lum, MD, Anne L. Coleman, MD, PhD JAMA. 2012;308(5):493-501 Background Visual impairment
More informationALK Inhibition: From Biology to Approved Therapy for Advanced Non-Small Cell Lung Cancer
ALK Inhibition: From Biology to Approved Therapy for Advanced Non-Small Cell Lung Cancer Dr. Ben Solomon Medical Oncologist, Thoracic Oncology Peter MacCallum Cancer Centre Melbourne, Australia Dr. D.
More informationSergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy
Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Ninth European International Kidney Cancer Symposium Dublin 25-26
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationHospice Eligibility August 2018
Hospice Eligibility August 2018 Objectives Identify who can make a hospice referral Review hospice eligibility and disease-specific prognostic indicators Review Open Access philosophy Who Can Make A Referral
More informationAlzheimer s Disease, Dementia, Related Disorders
Alzheimer s Disease, Dementia, Related Disorders Stage 7 on the FAST Scale signifies the threshold of activity limitation that would support a six-month prognosis. The FAST Scale does not address the impact
More informationPrimary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.
CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase
More informationCisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. Valle J et al. N Engl J Med 2010;362(14):
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer Valle J et al. N Engl J Med 2010;362(14):1273-81. Introduction > Biliary tract cancers (BTC: cholangiocarcinoma, gall bladder cancer,
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationThe road less travelled: what options are available for patients with advanced squamous cell carcinoma?
Robert Pirker Medical University of Vienna Vienna, Austria The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Disclosures Honoraria for advisory board/consulting
More informationWARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS,
Celgene Corporation 86 Morris Avenue Summit, New Jersey 07901 Tel 908-673-9000 Fax 908-673-9001 October 2012 NEW Indication Announcement for ABRAXANE for Injectable Suspension (paclitaxel protein-bound
More informationCPAG Summary Report for Clinical Panel Policy 1630 Bendamustine-based chemotherapy for first-line treatment of Mantle cell lymphoma (MCL) in adults
MANAGEMENT IN CONFIDENCE CPAG Summary Report for Clinical Panel Policy 1630 Bendamustine-based chemotherapy for first-line treatment of Mantle cell lymphoma (MCL) in adults The Benefits of the Proposition
More informationSIR-Spheres: Des essais cliniques à la pratique courante
SIR-Spheres: Des essais cliniques à la pratique courante Un focus sur le traitement du mcrc en échappement thérapeutique Dr. Michaël Vouche, MD. PhD. Université Libre de Bruxelles Institut Jules Bordet
More informationPaul Calabresi Award. From suboptimal to optimal treatment in older patients with cancer. Pierre Soubeyran, MD, PhD
Paul Calabresi Award From suboptimal to optimal treatment in older patients with cancer Pierre Soubeyran, MD, PhD Institut Bergonié, Université Bordeaux Segalen Health status-adapted cancer care Balance
More informationClinical Trials. Ovarian Cancer
1.0 0.8 0.6 0.4 0.2 0.0 < 65 years old 65 years old Events Censored Total 128 56 184 73 35 108 0 12 24 36 48 60 72 84 27-10-2012 Ovarian Cancer Stuart M. Lichtman, MD Attending Physician 65+ Clinical Geriatric
More informationNPAC+PERT+TRAS Regimen
Regimen Monograph Regimen Name Drug Regimen Cycle Frequency Premedication and Supportive Measures Dose Modifications Adverse Effects Interactions Drug Administration and Special Precautions Recommended
More informationPhase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial
Phase I Study of Carfilzomib and Panobinostat for Patients with Relapsed and Refractory Myeloma: A Multicenter MMRC Clinical Trial Jonathan L. Kaufman, Todd Zimmerman, Cara A. Rosenbaum, Anuj Mahindra,
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationSetting The setting was secondary care. The economic study was carried out in the UK.
Cost-utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer Robinson P, von der Masse H, Bhalla S, Kielhorn A, Aristides M, Brown A, Tilden D
More informationMaintaining Long-Term Efficacy in the Elderly MDS Patient with Poor Performance Status
Hi, my name is Dr. Hetty Carraway. I am a staff physician at the Taussig Cancer Institute at the Cleveland Clinic. Welcome to Managing MDS. 1 As you all are aware, many of our patients with MDS are in
More informationMeet the Professor Dosing and toxicity management
Meet the Professor Dosing and toxicity management Lodovico Balducci & Catherine Terret Mrs. Marie O. 78 years Right breast tumor : 50 mm, upper outer quadrant, Node: 0 Biopsy (9 Dec 2009) Invasive ductal
More informationOUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER
& OUR EXPERIENCES WITH ERLOTINIB IN SECOND AND THIRD LINE TREATMENT PATIENTS WITH ADVANCED STAGE IIIB/ IV NON-SMALL CELL LUNG CANCER Interim Data Report of TRUST study on patients from Bosnia and Herzegovina
More informationAdjuvant Chemotherapy for Elderly Women with Breast Cancer: Matti S. Aapro, M.D. IMO Clinique de Genolier Switzerland
SIOG Berlin October 2009 Adjuvant Chemotherapy for Elderly Women with Breast Cancer: Immediate Benefit and Long-Term Risk Matti S. Aapro, M.D. IMO Clinique de Genolier Switzerland 1 2 BACKGROUND MESSAGE
More informationTrabectedin in ASTS. Le Cesne A, et al. J Clin Oncol. 2018;36(suppl): Abstract
Results of a Prospective Randomized Phase III T-SAR Trial Comparing Trabectedin vs Best Supportive Care (BSC) in Patients With Pretreated Advanced Soft Tissue Sarcoma (ASTS) Abstract 11508 Le Cesne A,
More informationCorrelations of Obesity, Comorbidity and Treatment: Implications for Survival Analysis and Interpretation
Correlations of Obesity, Comorbidity and Treatment: Implications for Survival Analysis and Interpretation Rachel Ballard-Barbash, MD, MPH Applied Research Program (ARP) Division of Cancer Control and Population
More informationOutline Pretransplant Essential data Why comorbidities are important? For patients with cancer For patients given allogeneic HCT
Comorbidities before Allogeneic Hematopoietic Cell Transplantation (HCT) The HCT-specific Comorbidity Index (HCT-CI) Mohamed Sorror, M.D., M.Sc. FHCRC Seattle, WA Outline Pretransplant Essential data Why
More informationLipoplatin monotherapy for oncologists
Lipoplatin monotherapy for oncologists Dr. George Stathopoulos demonstrated that Lipoplatin monotherapy against adenocarcinomas of the lung can have very high efficacy (38% partial response, 43% stable
More information1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
More informationLung cancer in the elderly. D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium
Lung cancer in the elderly D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium Incidence and mortality of all cancers and lung cancer in relation to age and gender (US) 120,000
More informationNPAC(W)+PERT+TRAS Regimen
Regimen Monograph Regimen Name Drug Regimen Cycle Frequency Premedication and Supportive Measures Dose Modifications Adverse Effects Interactions Drug Administration and Special Precautions Recommended
More informationMedical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce
Medical treatment of metastatic renal cell carcinoma (mrcc) in the elderly ( 65y): Position of a SIOG Taskforce Medical treatment of metastatic RCC in the elderly ( 65y): Members of the SIOG Taskforce
More informationRadiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York
Radiotherapy in DLCL is often worthwhile Dr. Joachim Yahalom Memorial Sloan-Kettering, New York The case for radiotherapy Past: Pre-Rituximab randomized trials Present: R-CHOP as backbone, retrospective
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationHodgkin Lymphoma in Older Patients
Hodgkin Lymphoma in Older Patients Andrew M. Evens, DO, MSc March 26 th, 2015 Professor of Medicine Chief, Division of Hematology/Oncology Director, Tufts Cancer Center Tufts Medical Center Elderly Hodgkin
More informationDisclosures for Dr. Peter Borchmann 48 th ASH Annual meeting, Orlando, Florida
Phase II Study of Pixantrone in Combination with Cyclophosphamide, Vincristine, and Prednisone (CPOP) in Patients with Relapsed Aggressive Non-Hodgkin s Lymphoma P Borchmann Universitaet de Koeln, Koeln,
More informationCLINICAL STUDY REPORT SYNOPSIS
CLINICAL STUDY REPORT SYNOPSIS Document No.: EDMS-PSDB-5412862:2.0 Research & Development, L.L.C. Protocol No.: R115777-AML-301 Title of Study: A Randomized Study of Tipifarnib Versus Best Supportive Care
More informationClinical Outcome in Patients with Aortic Stenosis
Clinical Outcome in Patients with Aortic Stenosis Is the Prognosis Worse in Patients with Low-Gradient Severe Aortic Stenosis? Yoel Angel BSc, Shemy Carasso MD, Diab Mutlak MD, Jonathan Lessick MD Dsc,
More informationWhy is co-morbidity important for cancer patients? Di Riley Associate Director Clinical Outcomes Programme
Why is co-morbidity important for cancer patients? Di Riley Associate Director Clinical Outcomes Programme Co-morbidity in cancer Definition:- Co-morbidity is a disease or illness affecting a cancer patient
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 11 April 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 11 April 2012 XGEVA 120 mg, solution for injection 1 glass vial of 120 mg/1.7 ml (CIP code: 217 253-8) 4 glass vials
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationNon-small cell lung cancer (NSCLC) accounts for 80% of
ORIGINAL ARTICLE Pooled Analysis of Elderly Patients with Non-small Cell Lung Cancer Treated with Front Line Docetaxel/Gemcitabine Regimen: The Hellenic Oncology Research Group Experience Athanasios G.
More informationPharmaco-epidemiological outcome research
Pharmaco-epidemiological outcome research Using the PHARMO-Eindhoven Cancer Registry linkage Lonneke van de Poll-Franse Professor of Cancer Epidemiology and Survivorship, Tilburg University & Head department
More informationCo-morbidity: a summary of issues from the NCIN Site-Specific Clinical Reference Groups Dr Mick Peake
Co-morbidity: a summary of issues from the NCIN Site-Specific Clinical Reference Groups Dr Mick Peake Clinical Lead, NCIN National Clinical Lead, NHS Cancer Improvement Questionnaire to Site- Specific
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationAdjuvant chemotherapy in older breast cancer patients: how to decide?
Adjuvant chemotherapy in older breast cancer patients: how to decide? H. Wildiers University Hospitals Leuven Belgium Wildiers H, Kunkler I, Lancet Oncol 2007 Biganzoli L, Wildiers H, Lancet Oncol. 2012
More informationBackground CPX-351. Lancet J, et al. J Clin Oncol. 2017;35(suppl): Abstract 7035.
Overall Survival (OS) With Versus in Older Adults With Newly Diagnosed, Therapy-Related Acute Myeloid Leukemia (taml): Subgroup Analysis of a Phase 3 Study Abstract 7035 Lancet JE, Rizzieri D, Schiller
More informationGeriatric screening tools in older patients with cancer
Geriatric screening tools in older patients with cancer Pr. Elena Paillaud Henri Mondor hospital, Créteil, France University Paris-Est Créteil CONFLICT OF INTEREST DISCLOSURE I have the following potential
More informationSupplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationClinical Impact of primary prophylaxis for FN in breast cancer patients. Prof. Young Jin Suh The Catholic University of Korea
Clinical Impact of primary prophylaxis for FN in breast cancer patients Prof. Young Jin Suh The Catholic University of Korea Objectives Describe the prevalence of febrile neutropenia in patients with breast
More informationBreast cancer (screening) in older individuals: the oncologist s viewpoint for the geriatrician
Breast cancer (screening) in older individuals: the oncologist s viewpoint for the geriatrician Hans Wildiers Medical oncologist, Leuven, Belgium Past chairman of the EORTC elderly task force President-elect
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationBCCA Protocol Summary for Adjuvant Therapy of Colon Cancer using
BCCA Protocol Summary for Adjuvant Therapy of Colon Cancer using Capecitabine Protocol Code Tumour Group Contact Physician GIAJCAP Gastrointestinal GI Systemic Therapy ELIGIBILITY: Resected Stage III or
More informationBC Cancer Protocol Summary for Treatment of Platinum Resistant Epithelial Ovarian Cancer with Bevacizumab and Vinorelbine
BC Cancer Protocol Summary for Treatment of Platinum Resistant Epithelial Ovarian Cancer with Bevacizumab and Vinorelbine Protocol Code Tumour Group Contact Physician UGOOVBEVV Gynecologic Oncology Dr.
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationHu J, Gonsahn MD, Nerenz DR. Socioeconomic status and readmissions: evidence from an urban teaching hospital. Health Aff (Millwood). 2014;33(5).
Appendix Definitions of Index Admission and Readmission Definitions of index admission and readmission follow CMS hospital-wide all-cause unplanned readmission (HWR) measure as far as data are available.
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationDATA ELEMENTS NEEDED FOR QUALITY ASSESSMENT COPYRIGHT NOTICE
DATA ELEMENTS NEEDED FOR QUALITY ASSESSMENT COPYRIGHT NOTICE Washington University grants permission to use and reproduce the Data Elements Needed for Quality Assessment exactly as it appears in the PDF
More informationLong term survival in EGFR positive NSCLC patient. Dr.ssa G. Zago Oncologia Medica 2 Istituto Oncologico Veneto, IOV
Long term survival in EGFR positive NSCLC patient Dr.ssa G. Zago Oncologia Medica 2 Istituto Oncologico Veneto, IOV Medical history and diagnosis Male, caucasian 60 years old Former smoker (stop > 15 years)
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationCharacteristics and treatment of DLBCL in elderly patients
Characteristics and treatment of DLBCL in elderly patients Lysa Experience or From Stephan to Ruth Eli 5/02/16 F.Peyrade Nice France Age at Diagnosis http://seer.cancer.gov/ E(x) 10,00 9,00 8,00 7,00 6,00
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) for glioblastoma multiforme - relapsed. August 2008
Bevacizumab (Avastin) for glioblastoma multiforme - relapsed August 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationTEMPLATE CASE REPORT FORM. Rapid Response Pharmacovigilance in Palliative Care
TEMPLATE CASE REPORT FORM Rapid Response Pharmacovigilance in Palliative Care The case report form is to be completed in compliance with PaCCSC Standard Operating Procedures 1 Staff email: Participant
More informationSupplementary Online Content
Supplementary Online Content Shurraw S, Hemmelgarn B, Lin M, et al. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based
More informationRisk stratification in the older patient; what are our priorities?
Risk stratification in the older patient; what are our priorities? Sonja Zweegman MD PhD Amsterdam The Netherlands Negative impact of age on survival Meta-analysis of European trials (MP vs MPT, VMP vs
More informationEASTERN COOPERATIVE ONCOLOGY GROUP
EASTERN COOPERATIVE ONCOLOGY GROUP E5204 INTERGROUP RANDOMIZED PHASE III STUDY OF POSTOPERATIVE OXALIPLATIN, 5-FLUOROURACIL AND LEUCOVORIN VS OXALIPLATIN, 5-FLUOROURACIL, LEUCOV- ORIN AND BEVACIZUMAB FOR
More information